FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
Recommended
FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
On January 26, 2023, the Food and Drug Administration approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->